SB
NGNE icon

Samsara BioCapital’s Neurogene NGNE Stock Holding History

Samsara BioCapital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54M Hold
1,717,127
– – 4.44% 6
2026
Q1 		$34.6M Hold
1,717,127
– – 3.36% 7
2025
Q4 		$35.4M Hold
1,717,127
– – 3.65% 6
2025
Q3 		$29.8M Hold
1,717,127
– – 3.89% 5
2025
Q2 		$25.7M Hold
1,717,127
– – 5.25% 5
2025
Q1 		$20.1M Hold
1,717,127
– – 3.59% 4
2024
Q4 		$39.3M Buy
1,717,127
+449,337
+35% +$16.7M 5.39% 5
2024
Q3 		$53.2M Hold
1,267,790
– – 10.22% 4
2024
Q2 		$46.1M Hold
1,267,790
– – 9.66% 4
2024
Q1 		$64.5M Hold
1,267,790
– – 9.98% 4
2023
Q4 		$24.6M Buy
+1,267,790
New +$18.2M 3.82% 6

Other funds holding NGNE

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital's NGNE Position: Q2 2026 in Review

Samsara BioCapital held its Neurogene (NGNE) position steady in Q2 2026 at 1,717,127 shares worth $54M. The position accounts for 4.44% of the portfolio, ranked #6.

Samsara BioCapital first reported a position in NGNE in Q4 2023 and has held it in 11 quarters since. The position peaked at $64.5M in Q1 2024. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Samsara BioCapital held 1,717,127 shares of Neurogene worth $54M as of Q2 2026.
  • Samsara BioCapital left its Neurogene share count unchanged in Q2 2026.
  • Neurogene made up 4.44% of Samsara BioCapital's portfolio in Q2 2026, its #6 holding.
  • Samsara BioCapital first reported a position in Neurogene in Q4 2023 and has held it in 11 quarters since.
  • Samsara BioCapital's Neurogene position peaked at $64.5M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.